Compare FSI & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FSI | CRDL |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | Canada | Canada |
| Employees | N/A | N/A |
| Industry | Recreational Games/Products/Toys | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.6M | 97.3M |
| IPO Year | 1999 | N/A |
| Metric | FSI | CRDL |
|---|---|---|
| Price | $6.86 | $1.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 56.4K | ★ 630.5K |
| Earning Date | 11-14-2025 | 11-13-2025 |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.14 | N/A |
| Revenue | ★ $38,563,427.00 | N/A |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $51.24 | N/A |
| P/E Ratio | $49.13 | ★ N/A |
| Revenue Growth | ★ 0.18 | N/A |
| 52 Week Low | $3.46 | $0.77 |
| 52 Week High | $11.48 | $1.59 |
| Indicator | FSI | CRDL |
|---|---|---|
| Relative Strength Index (RSI) | 37.77 | 52.30 |
| Support Level | $6.35 | $0.88 |
| Resistance Level | $7.13 | $1.11 |
| Average True Range (ATR) | 0.43 | 0.08 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 32.90 | 69.57 |
Flexible Solutions International Inc develops, manufactures, and markets specialty chemicals that slow the evaporation of water. Its business is organized into two segments: Energy and Water Conservation Products and Biodegradable Polymers. It offers a liquid swimming pool blanket under the WATERSAVR brand, which saves energy and water by inhibiting evaporation from the pool surface, and a chemical product called HEATSAV for use in swimming pools and spas to slow water evaporation. The firm also manufactures and markets water-soluble chemicals utilizing thermal polyaspartate biopolymers. It generates the majority of its revenues from the export of its products to international markets.
Cardiol Therapeutics Inc is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases. The company's main product candidate, CardiolRx, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart which are a Phase II multi-national trial, the ARCHER trial, in acute myocarditis; and a Phase II multi-center open-label pilot study in recurrent pericarditis.